There are currently 126 clinical trials in Gilbert, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Banner MD Anderson Cancer Center, Mercy Gilbert Medical Center, GSK Investigational Site and Banner MD Anderson Cancer Center ( Site 0028). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
NCT04651634
Recruiting
The proposed study in patients with previously untreated locally advanced head and neck squamous cell carcinoma (HNSCC) is designed to evaluate the efficacy and safety of three different doses of MIT-001 compared to the placebo in prevention of oral mucositis (OM) in patients with HNSCC who are undergoing concurrent chemoradiotherapy (CCRT).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/21/2023
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona
Conditions: Oral Mucositis, Head and Neck Squamous Cell Carcinoma
Register for Updates
Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies
NCT04649112
Recruiting
This is a Phase 1, nonrandomized, open-label, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR19B in adult study participants with CD-19 expressing malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/08/2022
Locations: Banner MDA, Gilbert, Arizona
Conditions: CD19 Expressing Malignancies, Hematologic Malignancy
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: Banner MD Anderson, Gilbert, Arizona
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19
NCT04911777
Recruiting
This is a clinical trial to evaluate the safety, PK, viral shedding and clinical effects of Pentarlandir™ UPPTA in patients with early COVID-19. Approximately 90 ambulatory subjects with mildly symptomatic early COVID-19, who have been diagnosed with COVID-19 within the prior 4 days will be enrolled.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
12/16/2021
Locations: Cactus Clinical Research, Inc., Gilbert, Arizona
Conditions: Coronavirus Disease 2019
Register for Updates